We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

141 hedge funds and large institutions have $843M invested in CytomX Therapeutics in 2018 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 42 increasing their positions, 43 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,438% more call options, than puts

Call options by funds: $2.72M | Put options by funds: $177K

160% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 15

32% more capital invested

Capital invested by funds: $637M → $843M (+$206M)

18% more funds holding

Funds holding: 119 → 141 (+22)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 43

1.44% less ownership

Funds ownership: 78.49% → 77.05% (-1.4%)

Holders
141
Holders Change
+22
Holders Change %
+18.49%
% of All Funds
3.23%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
39
Increased
42
Reduced
43
Closed
15
Calls
$2.72M
Puts
$177K
Net Calls
+$2.55M
Net Calls Change
+$2.58M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$69.7M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$10.5M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$7.5M
4
Renaissance Technologies
Renaissance Technologies
New York
+$7.02M
5
PC
PointState Capital
New York
+$4.4M

Top Sellers

Rank Fund Capital Flow
1
TG
TRV GP
Massachusetts
-$65.6M
2
BI
BVF Inc
California
-$23.7M
3
PA
Perceptive Advisors
New York
-$8.04M
4
Millennium Management
Millennium Management
New York
-$6.92M
5
PAG
Private Advisor Group
New Jersey
-$4.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$5.74M +$1.39M +48,536 +32%
JP Morgan Chase
27
JP Morgan Chase
New York
$5.72M -$1.21M -42,478 -17%
Bank of America
28
Bank of America
North Carolina
$5.68M +$2.24M +78,391 +65%
Charles Schwab
29
Charles Schwab
California
$5.64M +$624K +21,864 +12%
Russell Investments Group
30
Russell Investments Group
United Kingdom
$5.44M +$2.38M +83,448 +77%
Two Sigma Advisers
31
Two Sigma Advisers
New York
$5.37M +$1.9M +66,700 +55%
SFM
32
Sphera Funds Management
Israel
$5.12M +$571K +20,000 +13%
GIM
33
Granahan Investment Management
Massachusetts
$4.63M +$2.04M +71,448 +78%
PAM
34
Panagora Asset Management
Massachusetts
$4.52M -$818K -28,643 -15%
PC
35
PointState Capital
New York
$4.38M +$4.4M +154,000 New
TA
36
Teachers Advisors
New York
$4.09M +$2.57M +90,200 +168%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$3.85M +$167K +5,855 +5%
Morgan Stanley
38
Morgan Stanley
New York
$3.82M +$995K +34,876 +35%
Federated Hermes
39
Federated Hermes
Pennsylvania
$3.58M +$1.61M +56,582 +82%
Victory Capital Management
40
Victory Capital Management
Texas
$3.53M +$3.54M +124,030 New
CPC
41
Congress Park Capital
New York
$3.06M -$521K -18,250 -14%
BIM
42
Bogle Investment Management
Massachusetts
$2.98M -$2.61M -91,326 -47%
Deutsche Bank
43
Deutsche Bank
Germany
$2.39M +$354K +12,415 +17%
D.E. Shaw & Co
44
D.E. Shaw & Co
New York
$2.21M +$1.34M +47,034 +154%
OAM
45
Oxford Asset Management
United Kingdom
$2.2M -$2.81M -98,435 -56%
VIA
46
Vident Investment Advisory
Georgia
$2.17M +$614K +21,500 +37%
AllianceBernstein
47
AllianceBernstein
Tennessee
$2.11M -$220K -7,720 -9%
Acadian Asset Management
48
Acadian Asset Management
Massachusetts
$2.09M +$2.09M +73,289 New
ACI
49
AMP Capital Investors
Australia
$1.87M – – –
IHM
50
Iguana Healthcare Management
New York
$1.85M -$285K -10,000 -13%
1
2
3 4 5

CTMX Hedge Fund Activity: Q1 2018 in Review

141 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2018, worth a combined $843M — up 32% from $637M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new CTMX positions and 15 closed out — a net gain of 24 holders — while 42 added to existing stakes and 43 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $69.7M. The largest seller was TRV GP, cutting an estimated $65.6M.

  • 141 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2018, up from 119 in Q4 2017.
  • Funds reported $843M of CytomX Therapeutics stock for Q1 2018, up 32% quarter-over-quarter.
  • 39 funds opened new CytomX Therapeutics positions in Q1 2018 and 15 closed out, a net change of +24 holders.
  • The largest CytomX Therapeutics buyer in Q1 2018 was T. Rowe Price Associates, an estimated $69.7M added.
  • The largest CytomX Therapeutics seller in Q1 2018 was TRV GP, an estimated $65.6M sold.

Based on aggregated 13F filings for Q1 2018.